ELTROMBOPAG 25 MG COMP

This tender, identified by the reference number 261Y000226/13559, concerns the procurement of Eltrombopag 25 mg tablets. Eltrombopag is a medication used to treat low blood platelet counts (thrombocytopenia) in certain patients, such as those with chronic immune thrombocytopenia (ITP) or severe aplastic anemia. The tender likely originates from a healthcare institution or a government health agency responsible for supplying essential medicines. The specification '25 MG COMP' indicates the dosage and form of the drug, referring to 25 milligram compounded tablets. This procurement is critical for ensuring patient access to necessary treatments for blood disorders. The tender process will involve evaluating bids from pharmaceutical suppliers to secure a reliable and cost-effective supply of this medication. Further details regarding the quantity, delivery schedule, and specific tender requirements would typically be found in the full tender documentation, which is not provided here. The objective is to ensure the availability of Eltrombopag 25 mg for eligible patients.

This is a supplies contract in the health and medical services and general supplies sectors. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 40,152.

Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.